Citations

Clear

286 citation(s) found for "Perez, Edith".

The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis.
Andersson, Michael , López-Vega, José Manuel, Petit, Thierry , Zamagni, Claudio , Donica, Margarita, Kamber, Julia, Perez, Edith A.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 586-586

10.1200/jco.2015.33.15_suppl.586 Get It

Breast cancer brain metastases: Comprehensive review of tumor extent, histology and treatment on survival.
Crozier, Jennifer A. , Cornell, Lauren , Rawal, Bhupendra, Perez, Edith A. , Cornell, Lauren F

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 1059-1059

10.1200/jco.2015.33.15_suppl.1059 Get It

Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
Chumsri, Saranya , Serie, Daniel, Li, Zhuo , Pogue–Geile, Katherine L. , Soyano‐Muller, Aixa E., Mashadi-Hossein, Afshin , Warren, Sarah , Lou, Yanyan , Colón‐Otero, Gerardo , Knutson, Keith L. , Perez, Edith A. , Moreno‐Aspitia, Alvaro , Thompson, E. Aubrey , Serie, Daniel J, Knutson, Keith L.

Mayo Clinic

Clinical Cancer Research | February 26, 2019 | Volume: 25 | Issue: 14 | Pages: 4422-4430

10.1158/1078-0432.ccr-18-2206 | PMID 30808774 Get It

Abstract Purpose: Young age has been shown to be an independent predictor of poor outcome in breast cancer. In HER2-positive breast cancer, the effects of aging remain largely unknown. Experimental Design: A total of 4,547 patients were included [3,132 from North Central Cancer Treatment Group (NCCTG) N9831 and 1,415 from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31]. Pathologic stromal tumor-infiltrating lymphocyte (sTIL) and molecular tumor infiltrating lymphocyte (mTIL) signatures were evaluated. Results: In NCCTG N9831, comparable benefit of trastuzumab was observed in all patients [age ≤ 40; HR, 0.43; 95% confidence interval (CI), 0.28–0.66; P < 0.001; and age > 40; HR, 0.56; 95% CI, 0.45–0.69; P < 0.001]. Similar results were observed in NSABP B-31 (age ≤ 40; HR, 0.45; 95% CI, 0.29–0.68; P < 0.001; and age > 40; HR, 0.42; 95% CI, 0.33–0.54; P < 0.001). Among patients who received chemotherapy alone, younger age was associated with poor outcome in the hormone receptor–positive subset, but not the hormone receptor–negative subset, in both trials. Although there was no association between sTILs and age, a small, but significant increase in mTIL CD45 and some immune subset signatures were observed. Among patients who received chemotherapy alone, patients over 40 years of age with lymphocyte-predominant breast cancer had excellent outcome, with 95% remaining recurrence free at 15 years. Conclusions: Among patients treated with trastuzumab, there was no significant difference in outcome related to age. Our study suggests that trastuzumab can negate the poor prognosis associated with young age.
Standardized antiemetic regimens
Perez, Edith A., Perez, Edith A.

Mayo Clinic

American Journal of Health-System Pharmacy | February 21, 2019 | Volume: 54 | Issue: 20 | Pages: 2404-2404

10.1093/ajhp/54.20.2404 | PMID 9347105 Get It

An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data.
Asmann, Yan W. , Necela, Brian M. , Chen, Xianfeng , Kocher, Jean‐Pierre , Feldman, Andew L., Novak, Anne J. , Perez, Edith A. , Thompson, E. Aubrey , Wang, Chen , Maurer, Matthew J. , Habermann, Thomas M. , Slager, Susan L. , Doǧan, Ahmet , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e22171-e22171

10.1200/jco.2014.32.15_suppl.e22171 Get It

Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).
Kottschade, Lisa A. , Halyard, Michele Y. , Sloan, Jeff A. , Flickinger, Lynn M. , Harris, Lyndsay N. , Le‐Lindqwister, Nguyet, Boyle, Frances , McCaskill-Stevens, Worta J., Zujewski, Jo Anne , Piccart, Martine , Perez, Edith A. , Dueck, Amylou C. , Hillman, David W. , Wolff, Antonio C. , Gralow, Julie R. , Pritchard, Kathleen I. , Ellard, Susan L. , Azambuja, Evandro de , Zujewski, Jo Anne

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 647-647

10.1200/jco.2014.32.15_suppl.647 Get It

Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).
Bernath, Albert M., Northfelt, Donald W. , Hou, Xiaonan , Tenner, Kathleen , Tienchaiananda, Piyawan , Flickinger, Lynn M. , Chen, Beiyun, Chen, Helen X., Lingle, Wilma L., Pellegrino, Christine, Sponzo, Robert W., Reinholz, Monica M., Perez, Edith A. , Haluska, Paul , Ballman, Karla V. , Dueck, Amylou C. , Linden, Hannah M. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 632-632

10.1200/jco.2014.32.15_suppl.632 Get It

Identification and targeting of M-phase progression downstream of HER2 in trastuzumab-sensitive and -resistant breast cancer cell lines.
Thompson, E. Aubrey , Necela, Brian M. , Carr, Jennifer M., Kachergus, Jennifer M., Serie, Daniel, Asmann, Yan W. , Perez, Edith A. , Kalari, Krishna R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 612-612

10.1200/jco.2014.32.15_suppl.612 Get It

Genes associated with serum estrone, estrone conjugates, and androstenedione concentrations in postmenopausal women with estrogen receptor-positive breast cancer.
Dudenkov, Tanda M., Buzdar, Aman U. , Kubo, Michiaki , Batzler, Anthony , Jenkins, Gregory D. , Pietrzak, Tracy L., Northfelt, Donald W. , Perez, Edith A. , Williard, Clark, Nakamura, Yusuke , Wang, Liewei , Weinshilboum, Richard M. , Ingle, James N. , Robson, Mark E. , Carlson, Erin E. , Fridley, Brooke L. , Goetz, Matthew P. , Kalari, Krishna R. , Weinshilboum, Richard M.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 593-593

10.1200/jco.2014.32.15_suppl.593 Get It